Jazz Pharmaceuticals plc JAZZ

NAS: JAZZ | ISIN: IE00B4Q5ZN47   9/09/2026
241,31 USD (+0,52%)
(+0,52%)   9/09/2026
Grafiek Jazz Pharmaceuticals plc Grafiek Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc in het nieuws

2 september 2026 · Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences · Persbericht

31 augustus 2026 · Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA · Persbericht

27 augustus 2026 · Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases · Persbericht

26 augustus 2026 · Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases · Persbericht

25 augustus 2026 · U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma · Persbericht

10 augustus 2026 · Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio · Persbericht

3 augustus 2026 · Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results · Persbericht

20 juli 2026 · Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026 · Persbericht

17 juni 2026 · Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies · Persbericht

16 juni 2026 · Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia · Persbericht

Profiel Jazz Pharmaceuticals plc

Fabricage van farmaceutische preparaten
Farmaceutische producten: Andere
Gezondheidstechnologie
Productie

Mijn selecties